Evidence map›Paper›PMID 42039900›Full record

ReviewFrontiers in nutrition2026

Senkyunolides: a promising natural compounds for the treatment of migraine headaches.

Yu Long, Dan Li, Xuemin Jian, Zhi Yang, Ting Leng, Xilian Wang, Wanxue Zhang, Xinyun Ge, Nan Li, Yuan Yin and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu LongNational Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Dan LiSchool of Modern Chinese Medicine Industry, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xuemin JianNational Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Zhi YangNational Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Ting LengSchool of Modern Chinese Medicine Industry, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xilian WangCollege of Life Sciences and Agri-forestry, Southwest University of Science and Technology, Mianyang, China.
Wanxue ZhangNational Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Xinyun GeCollege of Life Sciences and Agri-forestry, Southwest University of Science and Technology, Mianyang, China.
Nan LiSchool of Modern Chinese Medicine Industry, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yuan YinNational Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Xiaoan LiNational Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine, ranked as the second most disabling neurological disorder globally, affects over 1 billion people, imposing a substantial worldwide burden. The complexity of its pathological mechanisms contributes to therapeutic limitations. While existing first-line drugs offer partial efficacy, their utility is often constrained by cardiovascular risks, medication-overuse headaches, low bioavailability, and high treatment costs, necessitating novel therapies that balance efficacy and safety. Notably, senkyunolides, core bioactive compounds derived from traditional anti-migraine herbs like

Indexed as

migrainepharmacokineticspharmacologysenkyunolidesstability

Identifiers

PMID42039900
PMCPMC13105966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.